Sarepta Therapeutics, Inc. Stock News

Sarepta Therapeutics, Inc. faces uncertainty after Elevidys' revenue decline and ESSENCE trial failure, leading to a 25% SRPT stock drop. SRPT's PMO franchise remains its cash engine, but regulatory reliance on real-world evidence and FDA unpredictability add risk to the investment thesis. Label contraction for Elevidys and margin pressures weigh on near-term outlook, with upside catalysts most...

Sarepta Pharmaceuticals Inc (NASDAQ: SRPT) stock is plummeting down, down 31.4% at $16.77 at last glance.

Sarepta Therapeutics Inc. shares plunged 37% on Tuesday after the biotechnology company reported disappointing trial results for two of its treatments targeting Duchenne muscular dystrophy (DMD). The stock fell to $15.28 on Tuesday's open, compounding a steep 80% decline in 2025 before the latest selloff.

The biotechnology company discloses disappointing trial data for two treatments for Duchenne muscular dystrophy.

Sarepta Therapeutics, Inc. ( SRPT ) Q3 2025 Earnings Call November 3, 2025 4:30 PM EST Company Participants Tamara Thornton Douglas Ingram - CEO & Director Louise Rodino-Klapac - President of Research & Development and Technical Operations Patrick Moss - Executive VP & Chief Commercial Officer Ryan Wong - Executive VP & CFO Conference Call Participants Anupam Rama - JPMorgan Chase & Co, Researc...

Shares of Sarepta sank 36% before the bell on Tuesday after a trial for two gene-targeted therapies for a muscle-wasting disease missed a key goal, deepening concerns about the company's treatment pipeline.

Sarepta's stock sank after studies of Duchenne muscular dystrophy treatments failed their primary endpoints.

Sarepta said on Monday that its late-stage study testing two gene-targeted therapies for Duchenne muscular dystrophy did not meet the main goal.